TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05819723

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAM score
Description: The CAM scores assess the presence of delirium rapidly and accurately and also differentiates delirium from other cognitive impairment with a sensitivity of 94-100% and specificity of 90-95%.~It is an algorithm that consists of four features:~(i) Acute and fluctuating variation in mental status, (ii) Inattention, (iii) Incoherent or disorganized thinking, and (iv) Altered level of consciousness. CAM scores indicate delirium if the first two features are present and either the third or fourth feature is present.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAM score
Description: The CAM scores assess the presence of delirium rapidly and accurately and also differentiates delirium from other cognitive impairment with a sensitivity of 94-100% and specificity of 90-95%.~It is an algorithm that consists of four features:~(i) Acute and fluctuating variation in mental status, (ii) Inattention, (iii) Incoherent or disorganized thinking, and (iv) Altered level of consciousness. CAM scores indicate delirium if the first two features are present and either the third or fourth feature is present.
Study: NCT06405282

Intervention type: OTHER
Intervention: Manual Lymphatic Drainage
Description: MLD is a gentle manual technique used to decongest swollen areas and redirect lymphatic flow to non-congested areas
Study: NCT05621122

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study. The control group (omnivours) will be compared with all otgher groups

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study. The control group (omnivours) will be compared with all otgher groups

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study. The control group (omnivours) will be compared with all otgher groups

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study. The control group (omnivours) will be compared with all otgher groups
Study: NCT06405282

Intervention type: DEVICE
Intervention: Near infrared spectroscopy
Description: Oxygen saturation measurement

Intervention type: DEVICE
Intervention: Temperature
Description: Thermal imaging

Intervention type: DEVICE
Intervention: Tissue Dialectic Constant
Description: TDC captured by lymphatic fluid scanning device
Study: NCT05621122

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study. The control group (omnivours) will be compared with all otgher groups
Study: NCT04961281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: injection of Dexmedetomidine ( 10 microgram/kg) + 10 cc saline injection nearby median nerve as hydro-dissection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: injection of triamcinolone ( 40 mg) + 10 cc saline injection nearby median nerve as hydro-dissection
Study: NCT05616546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: The vaccine used in this study will be a licensed seasonal inactivated influenza vaccine for intramuscular injection that is approved by the FDA. Enrolled subjects will receive licensed seasonal inactivated influenza vaccine (administered as a part of the study).
Study: NCT06404021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interventional cardiology procedures with proctoring system
Description: Interventional procedures are performed by utilizing a monitoring platform that provides real-time support without engineer in the electrophysiology laboratory

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interventional cardiology procedures with engineer in the electrophysiology laboratory
Description: Biomedical engineers supervise the performance of interventional cardiology procedures in the electrophysiology laboratory.
Study: NCT05815433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor Human Milk - Nutritional Replacement
Description: All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
Study: NCT05063968

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet is administered orally once on Day 1 and Day 9, respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-6019 tablet
Description: Tablet is administered fasted orally once on Day 1
Study: NCT06105515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic and Endoscopic Collaborative Surgery (LECS)
Description: Minimal invasive surgery in collaboration between endoscopy and laparoscopic surgery, to locally remove the tumor
Study: NCT05063968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-6019 tablet
Description: Tablet is administered after a high-fat meal orally once on Day 9
Study: NCT06264908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated self-management programme
Description: 8 weeks integrated management programme with three educational sessions. Group therapy sessions (6-8 participants per group) delivered by occupational therapists and rheumatology nurses.~1. Disease pathology and Pain management~2. Joint protection and stretching exercise~3. Psychosocial education~4. Aids prescription Each session will consist of education session, exercise session and group sharing sessions.
Study: NCT05178836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F520+F007
Description: Drug: F007~F007 is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).~Drug: F520~F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
Study: NCT06467071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SH+ combined with a session for PMLD
Description: The intervention integrates WHO's Self Help Plus (SH+) and a session for Post-Migration Living Difficulties (PMLD) for Syrian women. SH+ is a guided self-help program with five weekly sessions led by facilitators, aimed at managing stress and psychological distress without requiring a diagnosis. This scalable intervention is based on solid research, proven effective in reducing stress and preventing mental health disorders (Tol et al., 2020; Turrini et al., 2019). The PMLD session, based on WHO's Problem Management Plus (PM+), involves focus groups to identify post-migration challenges. Participants share experiences, learn coping strategies, discover local resources, and strengthen social support networks. This integrated approach aims to enhance mental health, address post-migration difficulties, and improve stress reduction skills, supporting adaptation to a new country.
Study: NCT05730868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: Soft tissue release will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
Study: NCT05063968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-6019 tablet
Description: Tablet is administered orally once daily for 14 Days continuously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet is administered orally once daily for 14 Days continuously
Study: NCT05192694

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed tomography
Description: Positron Emission Tomography
Study: NCT05134753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advanced PRF
Description: Advanced PRF will be placed for patients undergoing sinus augmentation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: PRF will be placed for patients undergoing sinus augmentation
Study: NCT05033093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Root Canal Sealants
Description: it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Root Canal Sealants
Description: it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Root Canal Sealants
Description: it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain
Study: NCT05730868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: Muscle energy Technique will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MFR & MET
Description: combination of myofascial release and muscle energy technique will be performed on the trapezius, suboccipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: traditional physical therapy devices are used to relieve pain and spam. this will include a hot pack, ultrasound, and TENS (Transcutaneous electrical nerve stimulation)
Study: NCT04789473

Intervention type: GENETIC
Intervention: Polygenic Risk Score Generation
Description: PRS will be calculated for gestational diabetes risk using both cohorts, participants wont have results returned to them during the study.

Intervention type: GENETIC
Intervention: Polygenic Risk Score Generation
Description: PRS will be calculated for gestational diabetes risk using both cohorts, participants wont have results returned to them during the study.
Study: NCT04984343

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.~After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.~Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have \>72 hours between beginning of each fraction.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.~After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.~Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have \>72 hours between beginning of each fraction.
Study: NCT05143567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care anticoagulation in absence of thrombotic complications
Description: Subgroup IA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IB - patients receive LMWH (enoxaparin) for the prevention or treatment of VTE Subgroup IC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care anticoagulation in presence of thrombotic complications
Description: Subgroup IIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) for the prevention or treatment of VTE Subgroup IIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
Study: NCT04625101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-827104
Description: Triple T-type calcium channel blocker.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active dosage form.
Study: NCT05143567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care anticoagulation in combination with elastic compression
Description: Subgroup IIIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE
Study: NCT05400538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biorepair Toothpaste + Mousse
Description: Domiciliary application of the products twice a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biorepair Toothpaste
Description: Domiciliary application of the product twice a day.
Study: NCT04749043

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculus Quest 2 Virtual Reality Device
Description: 30 min VR experience exposure for labor analgesia. VR experiences include swimming in the ocean, walking through forests, engaging in 3D puzzles, exploring virtual lands, or interacting with musical objects

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculus Quest 2 Virtual Reality Device
Description: 30 min VR experience exposure for labor analgesia. VR experiences include swimming in the ocean, walking through forests, engaging in 3D puzzles, exploring virtual lands, or interacting with musical objects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Description: 30 min exposure for labor analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Description: 30 min exposure for labor analgesia
Study: NCT04558541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensitivity to phonological rules
Description: Assess whether children with developmental language disorder (DLD) are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon; children with speech sound disorder (SSD) are not predicted to be sensitive to the same phonological patterns.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensitivity to semantic category cues.
Description: Assess whether all children, including those with DLD, show improved learning of OR rules when a semantic category cue is used.
Study: NCT05954208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vısual Arts Group Therapy Based On Watson's Human Care Model
Description: VAGT-WHCM was applied to the intervention group, consisting of six sessions, lasting 90 minutes on average, once a week in three groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing treatment
Description: The control group participated only in the routine follow-up, treatment and practices in the institution.
Study: NCT06227312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LADY 1 Pro, New Life Balance
Description: whole-body vibration training on the platform

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: calf raises and modified drop jumps
Study: NCT06181838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lesion extraction
Description: Tretinoin and benzoil peroxide used concurent in both groups as standard therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tretinoin
Description: Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
Study: NCT04983810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fadraciclib
Description: Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
Study: NCT05079802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double antibiotic paste mixed with chitosan nanoparticles
Description: Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with chitosan nanoparticles gel

Intervention type: DRUG
Group type: OTHER
Intervention: Double antibiotic paste mixed with propylene glycol
Description: Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with propylene glycol
Study: NCT03441022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amiigo Watch Only
Description: Subjects will be asked to wear a wrist band with capabilities to detect their heart rate or rhythm on the basis of PPG on either wrist around the time of their cardioversion procedure. Data will be acquired from the wrist band at the same time as the electrocardiogram (ECG) monitor to which subjects are hooked up for the purposes of the cardioversion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amiigo Watch + BodyGuardian
Description: Subjects will be sent home after the cardioversion with a 30 day heart monitor called the BodyGuardian. This device continuously monitors their heart rate and rhythm and they will wear this on the chest. Subjects will also wear the wrist monitor over the same 30 day period.
Study: NCT05521347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caffeine
Description: we employed a randomized crossover design to divide participants into a caffeine trial (CAF) and a placebo trial (PL). The CAF group took capsules with 3 mg/kg of caffeine, whereas the PL group took a placebo capsule. After a 1-h rest, the Stroop task, visual search ability test, and the shooting ability test were conducted.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: caffeine
Description: we employed a randomized crossover design to divide participants into a caffeine trial (CAF) and a placebo trial (PL). The CAF group took capsules with 3 mg/kg of caffeine, whereas the PL group took a placebo capsule. After a 1-h rest, the Stroop task, visual search ability test, and the shooting ability test were conducted.
Study: NCT05971992

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chicory-derived inulin-type β-fructans
Description: This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of prebiotic. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-weeks intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of prebiotic per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of maltodextrin. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-week intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of placebo per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
Study: NCT05891535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot assisted radical cystectomy without mono J ureteral stent placement
Description: Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot assisted radical cystectomy with mono J ureteral stent placement
Description: Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
Study: NCT06438094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft
Description: A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction of the CEJ with a composite restoration followed by root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft
Description: Reconstruction of the CEJ with a composite restoration will be performed in B+ and B- defects prior to root coverage surgery. A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.